Xheme develops nanoporosity-based polymer composite technologies that reduce oxidative stress in biological systems, thereby enhancing the viability and shelf life of blood and platelets. This technology addresses the inefficiencies in the storage of vital fluids, ultimately lowering costs associated with life-saving treatments.
Funding
$90K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The storage of blood, platelets, human milk, and cell therapeutics faces challenges due to oxidative stress, which reduces cell viability and shelf life, leading to inefficiencies and increased costs. Current storage methods often fail to adequately protect these biological materials from degradation.
Solution
Xheme develops nanoporosity-based polymer composite technologies designed to mitigate oxidative stress in biological systems, thereby enhancing the viability and shelf life of blood, platelets, human milk, and cell therapeutics. These programmable polymer composites can be tailored to meet the specific performance needs for storing vital fluids and reducing the cost of life-saving treatments. Xheme's materials are being designed to enhance the productivity of biological cells with sustainable measures.
Target Audience
The primary target audience includes biomedical companies, hospitals, blood banks, and research institutions involved in the storage and processing of blood, platelets, human milk, and cell therapeutics.
Features
- Nanoporous polymer composites that reduce oxidative stress at the cellular level.
- Customizable designs to address specific challenges in biomedical plastics and bioprocessing.
- Applications in blood storage, human milk preservation, and cell therapeutics yield enhancement.
- Materials designed to be non-toxic and eco-friendly.
- Potential for use in single-use bioreactors and as cell culture additives.